Back to Search
Start Over
Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease-modifying antirheumatic drugs have influenced the use of leflunomide.
- Source :
-
International journal of rheumatic diseases [Int J Rheum Dis] 2017 Nov; Vol. 20 (11), pp. 1795-1797. Date of Electronic Publication: 2015 Jul 14. - Publication Year :
- 2017
- Subjects :
- Antirheumatic Agents economics
Arthritis, Rheumatoid diagnosis
Arthritis, Rheumatoid economics
Australia
Biological Products economics
Clinical Decision-Making
Drug Costs legislation & jurisprudence
Drug Utilization Review
Health Expenditures trends
Humans
Immunosuppressive Agents economics
Leflunomide economics
Practice Patterns, Physicians' economics
Practice Patterns, Physicians' legislation & jurisprudence
Program Evaluation
Time Factors
Treatment Outcome
Antirheumatic Agents therapeutic use
Arthritis, Rheumatoid drug therapy
Biological Products therapeutic use
Drug Costs trends
Immunosuppressive Agents therapeutic use
Leflunomide therapeutic use
Practice Patterns, Physicians' trends
Subjects
Details
- Language :
- English
- ISSN :
- 1756-185X
- Volume :
- 20
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- International journal of rheumatic diseases
- Publication Type :
- Editorial & Opinion
- Accession number :
- 26176865
- Full Text :
- https://doi.org/10.1111/1756-185X.12717